Hold MDT with $80 hard stop and $89.07 re-entry trigger ahead of Q2 FY27 catalyst
The HOLD is correct given the binding constraints: technical distribution (26.6M shares, heaviest single-day volume in 13 months) rules out Overweight, while structural quality floor (47+ year dividend Aristocrat streak, $5.4B TTM FCF with 1.6x coverage, 65% gross margins, 13.5x forward P/E) rules out Underweight. The $80 hard stop is structurally superior to tighter alternatives that would whipsaw on retests. Buyback collapse 68% YoY ($3.24B → $1.04B) is a meaningful management signal against current prices, but macro headwinds (97% no-cut probability, 30Y at 4.5%+) cap the bearish case.
| Position | Action |
|---|---|
| Price between $85-87 | Do not add — stacked-bearish MA setup with confirmed 200 SMA break on 26.6M shares is genuine distribution |
| Failed retest of 50 SMA at $89.07 | Trim 10-15% rather than waiting for $92-93 |
| Bull case rebuild: Q2 FY27 >+12% revenue, >19.5% operating margin, AND confirmed close >$89.07 with MACD positive and RSI >50 | Add 15-20%, retest to Overweight |
| Bear case deepening: Q2 FY27 <+5% revenue OR margin <18% OR goodwill impairment announcement | Exit remaining position, downgrade to Sell |
| 200 SMA close below $87.24 | 48-hour re-evaluation event (not auto-exit) |
The 09/30 technical breakdown is a tactical shakeout, not a structural thesis break—MDT's 13.5x forward P/E on accelerating earnings (TTM $4.06→Forward $6.41), 3.34% dividend yield, and 14.4% FCF margin create a lopsided risk/reward opportunity where the market is mispricing an inflecting blue-chip.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $88.82 | bearish |
| 50 SMA | $89.07 | bearish |
| 200 SMA | $87.24 | bearish |
| MACD Line | -0.53 | bearish |
| MACD Signal Line | +0.17 | bearish |
| MACD Histogram | -0.70 | bearish |
| RSI (14) | 37.56 | neutral |
| Bollinger Lower Band | $86.53 | neutral |
| ATR (14) | $2.06 | neutral |
| Volume (09/30) | 26.6M | bearish |
| Avg Volume (~30 sessions) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close below $87.24
Then: 48-hour reassessment event rather than auto-exit
↩ rebuts: “Bear's 'breakdown confirmed' conclusion”
EV: +12-21% · concedes: The 09/30 candle was technically weak with 26.6M shares (3x average) closing below the 200 SMA; MACD did cross bearish (fresh cross, not extended); No near-term news catalyst identified; Macro environment (10Y at multi-year highs) creates headwinds for defensive sectors
Medtronic is not a sale but a slow leak — the forward P/E math is accounting fiction requiring simultaneous tax-rate, margin, and accretion assumptions that history says won't materialize; institutional distribution is escalating (not exhausting); the 200 SMA has been decisively breached in a stacked-bearish MA configuration; bonds yield 120bps more than the dividend eliminating defensive rotation; and $43.2B in goodwill (86% of equity) with negative tangible book value creates a $5-10B impairment risk that turns any operational hiccup into an equity event.
EV: $78–82 (downside to $73-77 / April 2026 low zone) · concedes: Q1 FY27 $1.14 EPS included discrete/one-time tax items — forward comparisons not clean; Dividend is real and has been maintained/raised historically; The $73-77 zone represents a level where value-oriented buyers may emerge
→ vs conservative: Conservative misreads distribution volume as institutional dumping when lower Bollinger Band + 200 SMA test at $87.24 is where institutional accumulation happens; ATR of $2.06 and elevated volatility justify wider stops, not smaller position size; 'falling knife' framing ignores that every major MDT low over the past decade has been tested and defended at the 200 SMA
→ vs neutral: Neutral treats sentiment silence as 'no information' when it is actually a counter-signal at 13.5x forward P/E in a 14% FCF margin business; Q2 FY27 print IS the catalyst and neutral's passivity will cause underpositioning; macro headwinds on defensive dividend payers create asymmetric setups capped by yield floor; waiting for confirmation before re-entry risks chasing a move that will come too late
| 7-9M |
| neutral |
Support: 87.24 · 86.53 · 85 · 80.5 · 76.96 | Resistance: 88.82 · 89.07 · 90.56 · 93.04 · 93.4
Short-term trend is bearish with all moving averages stacked below price (10 EMA $88.82 < 50 SMA $89.07 < 200 SMA $87.24, all declining), a fresh MACD bearish crossover confirmed, RSI at 37.56 neutral-leaning bearish, and Bollinger lower band at $86.53 already touched. Volume surged to 26.6M (~3x average) on a down day, signaling distribution. The 200 SMA at $87.24 is the critical long-term support level; a sustained close below would mark a major trend change, while a recovery above $89.07 (50 SMA) would neutralize the bearish setup.
Market Cap
$110.57B
Shares Outstanding
1.28B
Current Price
~$86.40
52-Week Range
$73.31 – $106.33
50-Day MA
$89.74
200-Day MA
$88.78
TTM P/E
21.3x
Forward P/E
13.5x
PEG Ratio
1.55
Price/Book
2.20x
Dividend Yield
3.34%
Beta
0.574
TTM Revenue
$37.54B
Q1 FY27 Revenue (ended 2026-07-31)
$9.756B
Q1 FY27 YoY Revenue Growth
+13.7%
TTM Gross Profit
~$24.5B
Gross Margin
65.3%
TTM Operating Income
~$7.3B
Operating Margin
19.3%
TTM EBITDA
$10.41B
EBITDA Margin
27.7%
TTM Net Income
~$5.2B
Net Margin
13.9%
TTM EPS
$4.06
Forward EPS
$6.41
Q1 FY27 Diluted EPS
$1.14
ROE
10.6%
ROA
5.1%
Total Assets
$93.31B
Total Equity
$50.23B
Total Debt
$28.15B
LT Debt
$25.57B
Net Debt
$26.41B
Debt/Equity
55.4%
Current Ratio
2.07
Goodwill
$43.2B
Tangible Book Value
-$3.2B
Working Capital
$12.6B
Cash and Short-term Investments
$8.8B
Inventory
$6.2B
TTM Operating Cash Flow
~$7.4B
TTM FCF
~$5.4B
FCF Margin
~14.4%
TTM CapEx
~$2.0B
TTM Dividends Paid
~$3.65B
Annual Dividend Per Share
$2.85/share
TTM Buybacks
~$1.18B
TTM Acquisitions
~$1.57B
Q1 FY27 Acquisition
$1.162B
D&A (Quarterly)
$729M
Tax Rate Range
13.5% – 31.4%
Normalized Tax Rate
~19%
Q1 FY27 Op. Cash Flow
$1.793B
Q1 FY27 FCF
$1.290B
Strengths
Concerns
Medtronic is a high-quality medical device incumbent with a diversified four-segment portfolio generating $37.5B in annual revenue. The company demonstrated strong Q1 FY27 reacceleration with 13.7% YoY revenue growth and 41% YoY EPS growth, validating expectations of significant forward EPS expansion (13.5x forward P/E vs. 21.3x TTM). With ~$5.4B in annual FCF supporting a 3.34% dividend yield and low 0.57 beta, MDT functions as a defensive income holding with optionality on med-tech innovation, though negative tangible book value and $43.2B in goodwill represent structural risks. The analyst maintains a constructive HOLD rating with a positive bias, targeting $105-110 on weakness toward the $82-85 support zone.
Macro: Fed is unambiguously on hold with "No Fed rate cuts in 2026" priced at 97% on Polymarket (~$8.7M volume). A chorus of Fed officials warn inflation is still too high, signaling more work to do on interest rates — hawkish but partly priced. Long-end yields are surging: 10Y Treasury touched highest level since 2002 with biggest monthly gain since 2022; September was painful for bonds with Dow/S&P posting monthly losses. Counter-signal: cooler CPI print provided dovish surprise. Soft-landing baseline remains intact with US recession odds at 8% (down 2pp week-over-week). AI/tech leadership is causing sector rotation away from defensives. USD has a \"higher-for-longer\" tone from elevated real rates.